share_log

BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday

Benzinga ·  Apr 9 10:43

U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday.

Shares of BlackBerry Limited (NYSE:BB) rose sharply during Tuesday's session.

The company announced a collaboration with Advanced Micro Devices, Inc. (NASDAQ:AMD), designed to revolutionize next-generation robotic systems by enabling new levels of low latency and jitter, as well as repeatable determinism.

BlackBerry shares jumped 9% to $3.1340 on Tuesday.

Here are some other big stocks recording losses in today's session.

  • Nurix Therapeutics, Inc. (NASDAQ:NRIX) jumped 19% to $16.42. Nurix Therapeutics announced extension of strategic collaboration with Sanofi to develop novel targeted protein degraders of STAT6.

  • Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares climbed 14% to $3.0650 after Piper Sandler initiated coverage on the stock with an Overweight rating and a price target of $9.

  • Lyell Immunopharma, Inc. (NASDAQ:LYEL) gained 10.5% to $2.42.

  • Wheels Up Experience Inc. (NYSE:UP) climbed 10.3% to $3.00.

  • XPeng Inc. (NYSE:XPEV) climbed 8.7% to $8.02.

  • Revance Therapeutics, Inc. (NASDAQ:RVNC) gained 8.6% to $4.8350.

  • Moderna, Inc. (NASDAQ:MRNA) gained 8.3% to $113.81.

  • NIO Inc. (NYSE:NIO) shares rose 7.7% to $4.7050. NIO filed its 2023 annual report on Form 20-F.

  • Absci Corporation (NASDAQ:ABSI) gained 7.4% to $6.06.

  • Hudbay Minerals Inc. (NYSE:HBM) climbed 7.2% to $8.01 after B of A Securities upgraded the stock from Neutral to Buy.

  • Coeur Mining, Inc. (NYSE:CDE) rose 7% to $5.06. Roth MKM analyst Joe Reagor initiated coverage on Coeur Mining with a Buy rating and announced a price target of $5.4.

  • Bilibili Inc. (NASDAQ:BILI) gained 5.6% to $11.70.

  • Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) gained 5.5% to $8.30.

  • Tesla, Inc. (NASDAQ:TSLA) shares rose 2.3% to $176.93. Goldman Sachs analyst Mark Delaney maintained Tesla with a Neutral and lowered the price target from $190 to $175, while Morgan Stanley analyst Adam Jonas maintained the stock with an Overweight and maintained a $310 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment